CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...
Phase 3
Barcelona, Spain and 105 other locations
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Barcelona, Spain and 40 other locations
together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Esca...
Phase 1
Barcelona, Spain and 27 other locations
The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 a...
Phase 1
Barcelona, Catalunya, Spain and 7 other locations
with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....
Phase 1
Barcelona, Spain and 14 other locations
monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...
Phase 1
Barcelona, Spain and 17 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Barcelona, Spain and 130 other locations
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Barcelona, Spain and 145 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Barcelona, Spain and 179 other locations
study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...
Phase 1, Phase 2
Barcelona, Spain and 74 other locations
Clinical trials
Research sites
Resources
Legal